Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07604662 · ClinicalTrials.gov registry record · NA
Real-Time Acute Kidney Injury Perioperative Prediction Clinical Trial
A NA study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- NA
- Development phase
- 25,518
- Enrollment target
NCT07604662: Clinical Trial NA study, sponsored by University of California, San Francisco.
NCT07604662 is a NA study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 25,518 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1719% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07604662, a NA study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 25,518 participants
- Enrollment target
Study Summary
This investigator-initiated, pragmatic trial evaluates whether displaying a machine learning (ML)- derived perioperative AKI risk score-alone or paired with an interruptive Best/Our Practice Advisory (BPA/OPA)-improves kidney-protective care and reduces kidney injury after non-obstetric surgery at UCSF. Approximately 75-100 attending anesthesiologists (clusters) are randomized 1:1:1 to: (a) Control (risk score hidden), (b) Score Only (visible preoperative AKI risk probability with passive KDIGO bundle recommendation), or (c) Score + BPA (visible risk plus interruptive KDIGO prompt for high-risk patients). CRNAs/residents follow their attending' s assignment. Adult inpatients (age ≥18) with expected overnight stay and eGFR ≥15 mL/min/1.73 m² are included; obstetrics, chronic dialysis, and kidney transplant patients are excluded. The underlying preoperative model was prospectively validated at UCSF and outperforms anesthesiologist risk estimation reported in the literature. The model was reviewed and approved by the AI Oversight Committee at UCSF. Primary endpoint is the continuous change in serum creatinine (mg/dL) from baseline to POD 1-2. Secondary outcomes include KDIGO-defined AKI, adherence to bundle elements (hemodynamics, balanced fluids, nephrotoxin avoidance, glycemic control), intraoperative hypotension time, fluid volumes, nephrotoxin exposure, perioperative hyperglycemia, length of stay, unplanned ICU transfer, readmission, dialysis, and in-hospital mortality. Data are obtained from the EHR; analysts are blinded. No direct subject interaction is planned; the investigators will request a waiver of patient consent. The study aims to demonstrate that ML-enabled, workflow-embedded decision support can safely and feasibly improve guideline concordant care and decrease early postoperative kidney injury.
Primary Outcome
Maximum continuous change in serum creatinine (mg/dL) from baseline to post-operative day 1-2
Interventions
- DEVICE EHR-Embedded AKI Risk Score
- DEVICE EHR-Embedded AKI Risk Score with Best Practice Advisory
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,518 participants |
| Start Date | 2026-10-15 |
| Est. Completion | 2027-12-15 |
| Phase | NA |
What is known before NCT07604662 opens enrollment
NCT07604662 is an interventional study that assigns participants to a tested intervention. Its 25,518 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1719% higher).
The record links to 0 conditions, and to 2 interventions - of which EHR-Embedded AKI Risk Score is the first listed.
NCT07604662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07604662 about?
NCT07604662 is a clinical study titled "Real-Time Acute Kidney Injury Perioperative Prediction Clinical Trial". This investigator-initiated, pragmatic trial evaluates whether displaying a machine learning (ML)- derived perioperative AKI risk score-alone or paired with an interruptive Best/Our Practice Advisory (BPA/OPA)-improves kidney-protective care and reduces kidney injury after non-obstetric surgery at U...
What is the current status of trial NCT07604662?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 25,518 participants. The study started on 2026-10-15. Estimated completion is 2027-12-15.
What interventions are being tested in trial NCT07604662?
The interventions under investigation include: EHR-Embedded AKI Risk Score (DEVICE), EHR-Embedded AKI Risk Score with Best Practice Advisory (DEVICE).
Who is sponsoring clinical trial NCT07604662?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07604662's enrollment target sits among peer trials
25,518 9th of 2000 higher than 1,992 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07300839 · 25,500 participants · Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
- NCT03175302 · 25,240 participants
PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI